Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: A luminometer (400) includes a light detector (630) configured to sense photons (135). The luminometer (400) includes an analog circuit (915a) configured to provide an analog signal (965) based on the photons (135) emitted from assay reactions over a time period and a counter circuit (915b) configured to provide a photon count (970) based on the photons (135) emitted from the assay reactions over the time period. The luminometer (400) includes a luminometer controller (905) configured to, in response to an analog signal value of the analog signal (965) being greater than a predetermined value, determine and report a measurement value of the photons (135) emitted from the assay reactions over the time period based on the analog signal value of the analog signal (965) and a linear function (1010). Optionally, the linear function (1010) is derived from a relationship between the analog signal (965) and the photon count (970).

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: Assays (100) may be performed with a luminometer (400) having a chassis (405) that may include a reaction vessel chamber (610). The luminometer (400) may also include a light passage (640) that intersects the reaction vessel chamber (610). The luminometer (400) may also include a cap (415) that, when in a closed configuration, prevents light emitted by external sources from entering the reaction vessel chamber (610) and from entering the light passage (640). The cap (415) may provide access to the reaction vessel chamber (610) when in an open configuration. The luminometer (400) may also include a calibration light source (460) optically coupled to one end of the light passage (640) and a light detector (630) optically coupled to another end of the light passage (640). The light detector (630) may include a sensing element for receiving light from the light passage (640).

Abstract: A copy-evident document and a method of printing a copy-evident document wherein a void pantograph is created including a first set of halftone elements and a second set of halftone elements different in modulation from the first set of halftone elements. An overlay including a white image with a plurality of halftone hole locations is preferably formed, wherein the halftone elements of the void pantograph are converted to the plurality of halftone hole locations. The overlay is then preferably merged with a background image, such that portions of the background image are visible at the halftone hole locations of the overlay when printed. The merged image is then printed on print media, wherein the portions of the background image that are printed are printed at locations where the holes locations are present in the overlay creating a copy-evident feature.

Abstract: The invention provides a composition comprising a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer for use in medicine, wherein said composition does not contain any pharmaceutically active agent.

Abstract: The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.

Abstract: A copy-evident document and a method of printing a copy-evident document wherein a void pantograph is created including a first set of halftone elements and a second set of halftone elements different in modulation from the first set of halftone elements. An overlay including a white image with a plurality of halftone hole locations is preferably formed, wherein the halftone elements of the void pantograph are converted to the plurality of halftone hole locations. The overlay is then preferably merged with a background image, such that portions of the background image are visible at the halftone hole locations of the overlay when printed. The merged image is then printed on print media, wherein the portions of the background image that are printed are printed at locations where the holes locations are present in the overlay creating a copy-evident feature.

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.

Abstract: A method of treating a subject includes providing a mobile telecommunications device including a processor, a transceiver coupled to the processor including a transmitter for generating pulsed electrical signals adapted to be coupled to an antenna, at least one memory device accessible by the processor. The mobile telecommunications device is positioned proximate to the subject. Pulsed electrical signals are begun to be generated to cause the transmitter to drive the antenna, wherein the antenna in response to the pulsed electrical signals emits a pulsed electromagnetic field (PEMF) that reaches the subject to provide treatment.

Abstract: The present invention relates to vesicular formulations for use in the treatment of pain and/or reduced mobility associated with a loss of lubrication and/or structural integrity and/or swelling of a collagen structure. It also relates to a method of treating pain such as joint pain or tendonitis comprising topically administering a vesicular formulation according to the invention.

Abstract: A closing device includes an element which can be moved along a path, a drive, an operating element for detecting a closing request, and detector for detecting the position of an ID transmitter paired with the vehicle. The drive is designed to move the movable element along the path, and a closing movement of the movable element is started via the drive if the actuation of an operating element is detected, if an ID transmitter paired with the vehicle is detected in a first position region within a time window t following the actuation of the operating element, and if the ID transmitter paired with the vehicle is not detected in the first position region at least for a duration s, which begins at least within the time window t, after being detected in the first position region within the time window t.

Abstract: The present invention relates to vesicular formulations for use in the topical administration of a therapeutic, metabolic, cosmetic or structural Agent Of Interest (“AOI”) and methods of administering an AOI.

Abstract: A closing device includes an element which can be moved along a path, a drive, an operating element for detecting a closing request, and detector for detecting the position of an ID transmitter paired with the vehicle. The drive is designed to move the movable element along the path, and a closing movement of the movable element is started via the drive if the actuation of an operating element is detected, if an ID transmitter paired with the vehicle is detected in a first position region within a time window t following the actuation of the operating element, and if the ID transmitter paired with the vehicle is not detected in the first position region at least for a duration s, which begins at least within the time window t, after being detected in the first position region within the time window t.

Abstract: A panel-like/sheet-like finishing element (11) for covering floors and walls, for example in the renovation of old buildings, is provided with heat-insulating and sound-absorbing properties if its interior (15) is provided, between outer covering layers (12, 13), with channel-forming undulating supporting structures (16) filled with high-density coarse granules (21). The supporting structures (16) are connected to the covering layers (12, 13) along the vertex lines (17) so as to provide wet-strength action, and the interior (15), between these covering layers, is sealed by enclosing edging strips (19) to provide wet-strength action, with the simultaneous inclusion of moisture-tight, but vapour-permeable, supporting layers (20) on covering layers (12, 13). If this finishing element (11) is mounted vertically, the granule-filled channels (14) run horizontally.

Abstract: The present invention relates to compositions containing vesicular formulations, kits, methods of preparation thereof or uses thereof. The present invention provides improved combinations of formulations, for topical use.

Abstract: The present invention relates to vesicular formulations for use in the topical administration of a biologically active agent, methods of administering a biologically active agent, a combined preparation comprising a vesicular formulation and a kit comprising a vesicular formulation.

Abstract: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.

Abstract: The present invention relates to vesicular formulations for use in the treatment of pain and/or reduced mobility associated with a loss of lubrication and/or structural integrity and/or swelling of a collagen structure. It also relates to a method of treating pain such as joint pain or tendonitis comprising topically administering a vesicular formulation according to the invention.